KHẢO SÁT TỈ LỆ SỬ DỤNG KHÁNG ĐÔNG KÉO DÀI TRÊN BỆNH NHÂN THUYÊN TẮC HUYẾT KHỐI TĨNH MẠCH ĐIỀU TRỊ NGOẠI TRÚ

Abstract

Introduction: Long-term anticoagulation in the treatment of venous thromboembolism (VTE) is a crucial issue to prevent recurrence. The use of extended anticoagulation therapy requires a balance between benefits and bleeding risks. Most studies focus on inpatient populations, leading to limited data on long-term anticoagulation usage in outpatient settings. Objective: This study was conducted to evaluate the rate of patients receiving anticoagulation therapy for more than 3 months among outpatients with venous thromboembolism treated at University Medical Center Ho Chi Minh City, Vietnam. Subjects: Outpatients with venous thromboembolism treated at University Medical Center Ho Chi Minh City from January 2022 to December 2023. Study design: A retrospective, cross-sectional descriptive study. Results: A total of 220 patients met the inclusion criteria, with a mean age of 63.8 ± 16.4 years, and a female-to-male ratio of 1.9:1. The most common comorbidities were hypertension (52.7%), obesity (32.3%), diabetes (29.1%), and cancer (14.1%). Additionally, 18.2% of patients had right ventricular dysfunction on echocardiography. Most patients were on extended anticoagulation therapy (> 3 months), accounting for 93.2%. Of these, 33.6% were treated for 3–6 months, 29.8% for 6–12 months, and 36.6% for more than 12 months. Among those treated for up to 3 months, DOACs (direct oral anticoagulants) were predominant at 80%, followed by VKA (vitamin K antagonists) at 13.3%, and Enoxaparin at 6.7%. For those treated beyond 3 months, DOACs were used in 88.3%, while VKAs accounted for 11.7%. Conclusion: The study showed that most outpatients with venous thromboembolism were prescribed extended anticoagulation therapy (> 3 months), with DOACs being the most commonly used drugs.